A major conditions strategy cannot replace a national cancer plan-patient advocates voice their concerns
Lancet Oncol
.
2023 May;24(5):425-427.
doi: 10.1016/S1470-2045(23)00145-6.
Authors
Roger Wilson
1
,
Emma Kinloch
2
,
Lydia E Makaroff
3
,
Anna Bailey-Bearfield
4
,
Richard Stephens
5
,
Janette Rawlinson
6
,
Kathy Oliver
7
Affiliations
1
Patient Advocate, Shropshire, UK. Electronic address: roger_wilson@allmail.net.
2
Salivary Gland Cancer UK, London, UK.
3
Fight Bladder Cancer, Oxfordshire, UK.
4
Pancreatic Cancer UK, London, UK.
5
Patient Advocate, Stevenage, UK.
6
Patient Advocate, West Midlands, UK.
7
International Brain Tumour Alliance, Surrey, UK.
PMID:
37142368
DOI:
10.1016/S1470-2045(23)00145-6
No abstract available
MeSH terms
Humans
Neoplasms* / epidemiology
Neoplasms* / therapy
Patient Advocacy*